STAT+: David Sackler acknowledges ‘moral responsibility’ to address opioid crisis, but refuses to pay settlement without immunity
Amid a contentious bankruptcy court trial, a member of the Sackler family that owns Purdue…
Category: STAT+
STAT+: As use of widely prescribed stimulants increases, experts see troubling parallels to opioid crisis
A new study found that the number of adults who used two widely prescribed stimulants…
STAT+: Verily makes its first major acquisition as it looks to transform clinical trials
On the heels of a series of prominent recent hires, Verily announced plans on Tuesday…
STAT+: Former Medivation exec charged with insider trading after buying stock ‘within minutes’ of learning of a deal
Just days before Pfizer (PFE) announced plans to acquire Medivation six years ago, the former…
STAT+: Pharmalittle: Roche reports Actemra shortages due to Delta variant; J&J exports Covid-19 shots made in Africa to Europe
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right…
STAT+: With $110 million and a boost from Oprah, maternal health startup Maven hits $1 billion valuation
On Tuesday, maternal and family virtual care platform Maven raised $110 million in late-stage financing…
STAT+: Discovery of rare mutation in a brain protein adds fuel to debate over cause of Alzheimer’s disease
In 2014, two siblings came to see Lena Kilander about some of the problems they’d…
STAT+: Pharmalittle: Merck is latest drug maker to end 340B discounts; ‘fractionation’ is promoted to stretch Covid-19 vaccines
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: Pfizer says ‘trust us’ when it comes to a Covid-19 booster; FDA OKs extra dose of the mRNA shots for some people
And so, another working week will soon come to an end. Not a moment too…
STAT+: Ellis Unger, an outspoken FDA veteran, resigns
WASHINGTON — A top FDA official known for speaking out against controversial drug approval decisions,…
STAT+: As Bluebird backpedals from Europe, small gene and cell therapy players face tough hurdles
After Bluebird Bio (BLUE) announced plans this week to end commercial operations in Europe, the…
STAT+: New immunotherapy approach wiped out tumors in two patients with advanced lung cancer, study reports
Drugs called immune checkpoint inhibitors have transformed treatment of many types of tumors, but metastatic…
STAT+: Pharmalittle: Biden pushes Congress to let Medicare negotiate drug prices; National Academies failed to disclose pharma-friendly committee ties
Rise and shine, another busy day is on the way. And it will be steamy…
.jpg)
Opinion: STAT+: To ensure equity and accuracy, clinical research must reflect the diversity of patients
In the journey from lab to label for a new and promising treatment, clinical research…
STAT+: Veterans Affairs declines to cover Biogen Alzheimer’s drug over effectiveness and safety concerns
The Department of Veterans Affairs has decided not to cover a new Alzheimer’s drug from…
STAT+: Pharmalittle: WHO to lead trial testing three drugs as Covid-19 salves; patient access to antibiotics lacking in wealthy countries
Hello, everyone, and how are you this fine, sunny morning? The middle of the week…
STAT+: RNA firm GreenLight Biosciences to go public in $1.2 billion deal
A Massachusetts-based synthetic biology company whose research ranges from developing pesticide alternatives for crops to…
STAT+: As tech giants double down on sleep tracking, providers want more proof it’s useful
Wearable sleep tracking has been an alluring target for tech giants for nearly a decade….
STAT+: ‘We don’t unlearn’: What the pandemic has taught regulators about real-world data
During the pandemic, regulatory agencies deployed emergency measures left and right to speed care to…
.jpg)
STAT+: ‘Things are so messed up’: Patient access to antibiotics is lacking even in the wealthiest countries
Although 18 innovative antibiotics were approved by regulators in the wealthiest nations over the past…
STAT+: Pharmalittle: Bluebird to wind down European operations over pricing; whither the FDA’s accelerated approval pathway?
Good morning, everyone, and how are you today? The sun is trying to peek through…
STAT+: After leaving patients in limbo, Pfizer agrees to sell a discontinued glaucoma drug
After months of controversy, Pfizer (PFE) has reached a deal to sell a decades-old eye…
STAT+: Pharmalittle: Still no word from Biden on a new FDA chief; CMS pulls ‘most favored nation’ rule for lowering drug prices
Good morning, everyone, and welcome to another working week. We hope the weekend respite —…
STAT+: As White House mulls FDA commissioner job, a sign of industry backing for Woodcock surfaces
Shortly after the Biden administration took office, a letter-writing campaign erupted over who should be…
Opinion: STAT+: Viruses, variants, and the business of health care: Preparing for another wave now and the years ahead
We’re in a new phase of the Covid-19 pandemic in which new mutations will have…
STAT+: In the feeding frenzy of health tech dealmaking, the little fish wield power
The fickle market only lets executives at health care startups control so much, but for…
STAT+: Adagio raises $300 million in IPO, looks to advance Covid-19 antibody therapy
Adagio Therapeutics, a Waltham startup advancing COVID-19 antibody treatments, is going public Friday just over…
STAT+: Pharmalittle: FDA expects to have Covid booster plan by early September; feds halt Novavax vaccine funding
Wakey-wakey, everyone. It’s Friday! You can sip your cup of stimulation with satisfaction this morning:…
STAT+: A federal appeals court throws into question the fate of ‘skinny labels’ — and access to generic drugs
In a decision with enormous implications for the U.S. health care system, a federal appeals…
STAT+: Scientists plumbing mysterious RNAs in the human genome find a possible treatment for an inherited disorder
When hundreds of scientists from around the world finally pieced together a draft of the…
STAT+: U.K. antitrust watchdog issues a provisional ruling that Pfizer engaged in price gouging
After being forced to reassess its original findings, a U.K. antitrust watchdog has issued a…
STAT+: Pharmalittle: HHS watchdog to review FDA approval of Alzheimer’s drug; Moderna sold $4.2 billion of its Covid-19 vaccine
Good morning, everyone, and how are you today? We are doing just fine, thank you….
Opinion: STAT+: Human-centered design can boost clinical trial recruitment, retention
By disrupting the clinical trials process, the Covid-19 pandemic has served as a tipping point…
STAT+: Athira cited altered studies in $15 million NIH grant application, creating legal risk
Biotech company Athira Pharma, which is in turmoil after its chief executive was found to…
STAT+: Bayer inks a $1.5 billion deal for a biotech with a proprietary drug discovery platform
In a bid to quickly broaden its drug discovery abilities, Bayer (BAYRY) has reached a…
STAT+: Federal watchdog will review the controversial FDA approval of Biogen’s Alzheimer’s drug
The federal watchdog at the Department of Health and Human Services will review the process…
STAT+: Canadian agency loses a battle in effort to force a drug maker to lower ‘excessive’ pricing
In a withering ruling, a Canadian appeals court overturned a controversial decision issued four years…
STAT+: Pharmalittle: FDA aims to fully approve Pfizer Covid-19 vaccine by Labor Day; SoftBank grabs $5 billion stake in Roche
Rise and shine, everyone, the middle of the week is already here. Congratulations on making…
STAT+: FDA to importer: keep your active pharma ingredients away from weed killer and antifreeze
What do weed killer, engine antifreeze coolant, dry wall repair products, and active pharmaceutical ingredients…
STAT+: STAT+ Conversation: Dealing with the Delta variant
Editor’s note: A livestream of the conversation will be embedded below at 1 p.m. ET….
STAT+: Pharmalittle: Sanofi to pay $3.2 billion to buy Translate Bio; COVAX struggles with Covid-19 vaccine distribution
Hello, everyone, and how are you today? Cloudy skies are hovering this morning over the…
STAT+: Amylyx is breaking all of biotech’s unwritten rules — and still raising impressive sums
If you want to raise big money in biotech, there are a few unwritten rules….
STAT+: Sanofi pays $3 billion to purchase Translate, raising stakes around mRNA technology
Major drug makers are getting into mRNA, the technology behind the Moderna and Pfizer-BioNTech Covid…
STAT+: ‘Deeply disappointed’: FTC pulls pay-to-delay case after losing authority to force drug makers to relinquish profits
The Federal Trade Commission has reluctantly withdrawn a remaining claim in a lawsuit over a…
STAT+: Pharmalittle: Pfizer and Moderna raise Covid-19 vaccine prices for Europe; FDA to speed full approval of Pfizer shot
Good morning, everyone, and welcome to another working week. We hope the weekend respite —…
Opinion: STAT+: Stifling biopharma mergers would kill the innovation economy that generates new therapies
The headlines speak of a biotech boom with news of company launches, oversubscribed private financings,…
STAT+: Pharmalittle: Remdesivir props up Gilead’s declining fortunes; U.K. fines drug maker for price hikes
Good morning, one and all. Damian Garde here, filling in for Ed Silverman in the…
STAT+: Alzheimer’s scientists critique Cassava Sciences’ study results — overblown, inappropriate, uninterpretable
Independent researchers are expressing doubts about the purported benefits of an experimental treatment for Alzheimer’s…
STAT+: Pharmalittle: Emergent to resume Covid-19 vaccine production; FDA OKs first interchangeable biosimilar insulin
Hello, everyone, and how are you today? We are just fine, thank you, despite gray…
STAT+: Here’s why simply approving Aduhelm can’t guarantee a golden age of Alzheimer’s R&D
Since the controversial approval of the Alzheimer’s drug Aduhelm, both the Food and Drug Administration…